WuXi AppTec acquisition enhances its biometrics services for clinical development

6 May 2019

Acquisition will help customers to shorten time-to-market of new drugs.

WuXi AppTec has acquired Pharmapace, a US-based clinical research services company with expertise of providing high-quality biometrics services for all phases of clinical trials, regulatory submissions, and post-marketing support. Upon the closing of this acquisition, Pharmapace will become a wholly-owned subsidiary of WuXi Clinical - the clinical CRO arm of WuXi AppTec - and will continue to focus on growing its core biometrics competences and integrate with WuXi Clinical's other clinical development services.

WuXi AppTec acquisition enhances its biometrics services for clinical development

Founded in 2013 in San Diego, California, Pharmapace provides a full range of biometrics services for all phases of clinical trials, including clinical and statistical programming, data management, biostatistics, clinical data integration, and medical writing with clients in North America, Europe and Asia. With this acquisition, WuXi Clinical expanded its biometrics capabilities in the US and Europe. By integrating Pharmapace and WuXi Clinical China based biometrics teams, the company will be able to provide its global customers with efficient and cost-effective biometrics service essentially round the clock.

With the addition of Pharmapace, WuXi Clinical collectively has over 850 employees located in China and the US, together with its close partners in Europe, Asia Pacific, the company can provide customers full clinical development services, as well as functional service provider (FSP) worldwide. China's recent regulatory reforms that embrace overseas trial data provide an unprecedented opportunity for innovators around the world to accelerate and integrate clinical development both regionally and globally through the WuXi Clinical organization.

"Pharmapace is excited to join WuXi AppTec, a world-class organization with superior leadership and long history of success, a like-minded focus with a customer-centric approach, as well as a vision to enable every company to discover and develop drugs for the patients around the world. This combination now allows us to leverage WuXi AppTec's vast resources to offer customers a truly global solution from preclinical development to clinical development and regulatory submission," said Dr Larry Shen, President and CEO of Pharmapace.

"We are very pleased to welcome Pharmapace to WuXi AppTec. Larry and his leadership team have built a highly reputable biometrics organization in the US," said Edward Hu, Co-CEO of WuXi AppTec. "This acquisition further enhances WuXi Clinical's drug development expertise and biometrics capabilities and lays the foundation for the creation of an integrated global biometrics service platform to efficiently and cost effectively provide customers seamless biometrics services globally. Together, we are able to shorten time-to-market of new drugs and to achieve the dream that 'every drug can be made and every disease can be treated'."

Read More

Related news

Legacy ramps up preparations for new Russian track and trace sterilisation regulations

Legacy ramps up preparations for new Russian track and trace sterilisation regulations

18 Jul 2019

Company to install new inspection cameras with higher resolution to ensure readability of more complex codes demanded by the Russian mandated crypto coding.

Read more 
Combination technique improves polysaccharide characterization

Combination technique improves polysaccharide characterization

17 Jul 2019

The AF4-MALS-RI method makes possible the accurate determination of molecular weight distribution of polysaccharide macromolecules.

Read more 
Lubrizol integrates personal, home and health care divisions

Lubrizol integrates personal, home and health care divisions

16 Jul 2019

The new brand - Lubrizol Life Sciences - aims to maximize client speed-to-market, providing enhanced solutions.

Read more 
Bosch finds buyers for its packaging machinery business

Bosch finds buyers for its packaging machinery business

16 Jul 2019

CVC Capital Partners to " take the business forward in the years ahead, and to make it even more competitive".

Read more 
New state-of-the-art cleanroom boosts production of anticancer drugs

New state-of-the-art cleanroom boosts production of anticancer drugs

15 Jul 2019

The GMP facility has been specifically designed to deliver the next generation of anticancer blockbuster ADC drugs for patients globally.

Read more 
Colorcon chooses the Netherlands for new starch manufacturing plant

Colorcon chooses the Netherlands for new starch manufacturing plant

12 Jul 2019

The plant will provide a secure second source of supply of Starch 1500, Pregelatinized Maize Starch.

Read more 
GSK opens new continuous manufacturing facilities in Singapore

GSK opens new continuous manufacturing facilities in Singapore

11 Jul 2019

Opening of continuous manufacturing facilities and expansion of production building will boost capabilities to accelerate the supply of new breakthrough medicines to patients globally.

Read more 
Eisai collaborates with University of Dundee on cancer drug discovery

Eisai collaborates with University of Dundee on cancer drug discovery

10 Jul 2019

It is hoped that research into PROTACs will lead to new drug discoveries for proteins present in cancer, which are difficult to treat with conventional small molecule inhibitors.

Read more 
Onyx Scientific makes strategic investment in commercial API licence

Onyx Scientific makes strategic investment in commercial API licence

10 Jul 2019

Investment fills the growing gap in the market for manufacturers that have the niche capabilities to deliver small-scale commercial API projects.

Read more 
I Holland to share the science behind tool maintenance

I Holland to share the science behind tool maintenance

9 Jul 2019

Proper maintenance - rather than replacement - of compression tooling will improve profitability.

Read more